Key facts
- Starfish Bioscience’s last known valuation is $5.3M (Jun 2024).
- It has raised $2.9M; the latest was Seed Round ($1.1M) in Jun 2025.
- Notable investors include Bpifrance, IRDI Capital Investissement, Bernard Magrey Start-Up Win, Seventure, Unitec (Accelerator/Incubator).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Starfish Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Starfish Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starfish Bioscience
Provider of a biotechnological system for agriculture and viticulture intended to regenerate soils and minimize environmental impact. The company offers analysis of soil microbiomes and the development of solutions to improve soil health and crop yields, enabling farmers to regenerate soils through the restoration of their microbiomes to improve sustainability and productivity while minimizing environmental impact.
- Sector
- Materials and Resources
- HQ
- Bordeaux, France
- Founded
- 2023
- Employees
- 8
- Website
- starfishbio.com/
- Ownership
- Privately Held (backing)
Starfish Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starfish Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starfish Bioscience in its N-PORT filings yet. We sweep new filings monthly.